BridgeBio Pharma, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
BridgeBio Pharma, Inc. (BBIO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- BridgeBio Pharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.63M, a 31.72% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.47M, a 47.48% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.46M, a 47.23% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.21M.
- BridgeBio Pharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $4.90M, a 19.27% increase from fiscal 2024.
- BridgeBio Pharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $4.11M, a 1.93% increase from fiscal 2023.
- BridgeBio Pharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $4.03M.
- BridgeBio Pharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $3.09M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.09M 10-Q · filed 2026-08-10 | $4.55M derived: sum of 3 quarters · filed 2026-08-10 | $5.77M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.47M 10-Q · filed 2026-05-07 | $2.92M derived: sum of 2 quarters · filed 2026-05-07 | $4.14M derived: sum of 3 quarters · filed 2026-05-07 | $5.37M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.67M derived: sum of 2 quarters · filed 2026-02-24 | $3.91M derived: sum of 3 quarters · filed 2026-08-10 | $4.90M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $2.45M derived: sum of 2 quarters · filed 2026-08-10 | $3.44M 10-Q · filed 2025-10-29 | $4.43M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.23M 10-Q · filed 2026-08-10 | $3.22M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-03-31 | $994.00K 10-Q · filed 2026-05-07 | $1.99M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $991.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.11M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $3.12M 10-Q · filed 2025-10-29 | |||
| 2023-12-31 | $4.03M 10-K · filed 2026-02-24 | |||
| 2021-03-31 | $1.36M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $3.09M 10-K · filed 2021-02-25 | |||
| 2020-03-31 | $541.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |